68Ga Bombesin PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Noncontributory Conventional Imaging

reportActive / Technical Report | Accession Number: AD1073045 | Open PDF

Abstract:

Purpose 68Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 68Ga-RM2 is a synthetic bombesin receptor antagonist that targets gastrin-releasing peptide receptors GRPr. GRPr proteins are highly overexpressed in several human tumors, including prostate cancer PC. Methods We enrolled 49 men with biochemically recurrent PC from May 2017 to Sep 2018, 59-79 year-old meanstandard deviation SD 69.85.4. Imaging started at 40-89 minutes meanSD 56.328.6 after injection of 127.5-149.7 MBq meanSD 141.64.4 of 68Ga-RM2 using a time-of-flight TOF-enabled simultaneous positron emission tomography PET magnetic resonance imaging MRI scanner. T1-weighted T1w, T2-weighted T2w and diffusion-weighted images DWI were acquired. Results All patients had rising prostate specific antigen PSA range 0.2-124.0 ngmL meanSD 6.619.3 and negative CI CT or MRI, and 99mTc MDP bone scan prior to enrollment. The observed 68Ga-RM2 PET detection rate was 73.5. 68Ga-RM2 PET identified recurrent PC in 36 of the 49 participants. PSA ranged 0.2-9.1 meanSD 1.92.5 in patients with negative scans and 0.2-124.0 meanSD 8.220.4 in patients with positive scans. Conclusions 68Ga-RM2 PET can be used for assessment of GRPr expression in patients with biochemically recurrent PC. High uptake in multiple areas compatible with cancer lesions suggests that 68Ga-RM2 is a promising PET radiopharmaceutical for localization of disease in participants with biochemically recurrent PC and negative conventional imaging.

Author(s):
Iagaru, Andrei
Author Organization(s):
THE LELAND STANFORD JUNIOR UNIVERSITY Stanford United States
Descriptive Note:
Technical Report,30 Sep 2017,29 Sep 2018
Pagination:
0011

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution:
Approved For Public Release
Distribution Statement:
Approved For Public Release;

RECORD

Collection: TR
Subject Terms
Joint Capability Areas:
JCA_5_Command and Control; JCA_5.3_Planning; JCA_1.2.5_Lessons Learned; JCA_1.3.2_Personnel Management
Communities of Interest:
No COI(s) Identified
Descriptor(s):
Prostate cancer, magnetic resonance imaging, positron emission tomography, peptides, proteins, antigens, lesions, biological markers
Field(s)/Group(s):
Medicine and Medical Research, Biochemistry, Radiobiology
Keyword(s):
Bombesin, mri (magnetic resonance imaging), pet (positron emission tomography), 68Ga Bombesin pet mri, clinical research, grpr (gastrin releasing peptide receptors), 68Ga RM2, GRPr proteins, pc (Prostate cancer), dwi (diffusion weighted images), bone scans, psa (prostate specific antigen), biochemically recurrent PC
Report Date:
2018 Oct 01
Creation Date:
2019 May 17